Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
- PMID: 38424845
- DOI: 10.1093/jbi/wbaa110
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Abstract
Gene expression profiling has reshaped our understanding of breast cancer by identifying four molecular subtypes: (1) luminal A, (2) luminal B, (3) human epidermal growth factor receptor 2 (HER2)-enriched, and (4) basal-like, which have critical differences in incidence, response to treatment, disease progression, survival, and imaging features. Luminal tumors are most common (60%-70%), characterized by estrogen receptor (ER) expression. Luminal A tumors have the best prognosis of all subtypes, whereas patients with luminal B tumors have significantly shorter overall and disease-free survival. Distinguishing between these tumors is important because luminal B tumors require more aggressive treatment. Both commonly present as irregular masses without associated calcifications at mammography; however, luminal B tumors more commonly demonstrate axillary involvement at diagnosis. HER2-enriched tumors are characterized by overexpression of the HER2 oncogene and low-to-absent ER expression. HER2+ disease carries a poor prognosis, but the development of anti-HER2 therapies has greatly improved outcomes for women with HER2+ breast cancer. HER2+ tumors most commonly present as spiculated masses with pleomorphic calcifications or as calcifications alone. Basal-like cancers (15% of all invasive breast cancers) predominate among "triple negative" cancers, which lack ER, progesterone receptor (PR), and HER2 expression. Basal-like cancers are frequently high-grade, large at diagnosis, with high rates of recurrence. Although imaging commonly reveals irregular masses with ill-defined or spiculated margins, some circumscribed basal-like tumors can be mistaken for benign lesions. Incorporating biomarker data (histologic grade, ER/PR/HER2 status, and multigene assays) into classic anatomic tumor, node, metastasis (TNM) staging can better inform clinical management of this heterogeneous disease.
Keywords: HER2-enriched; basal; breast cancer; luminal; molecular subtype.
© Society of Breast Imaging 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x. World J Surg Oncol. 2016. PMID: 27619909 Free PMC article.
-
Association of poor prognosis subtypes of breast cancer with estrogen receptor alpha methylation in Iranian women.Asian Pac J Cancer Prev. 2012;13(8):4113-7. doi: 10.7314/apjcp.2012.13.8.4113. Asian Pac J Cancer Prev. 2012. PMID: 23098526
-
Association between mammographic density and basal-like and luminal A breast cancer subtypes.Breast Cancer Res. 2013;15(5):R76. doi: 10.1186/bcr3470. Breast Cancer Res. 2013. PMID: 24008056 Free PMC article.
-
Molecular subtypes and imaging phenotypes of breast cancer.Ultrasonography. 2016 Oct;35(4):281-8. doi: 10.14366/usg.16030. Epub 2016 Jul 21. Ultrasonography. 2016. PMID: 27599892 Free PMC article. Review.
-
Molecular Phenotype, Multigene Assays, and the Locoregional Management of Breast Cancer.Semin Radiat Oncol. 2016 Jan;26(1):9-16. doi: 10.1016/j.semradonc.2015.08.002. Semin Radiat Oncol. 2016. PMID: 26617205 Review.
Cited by
-
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression.Cancer Metastasis Rev. 2024 Jun;43(2):823-844. doi: 10.1007/s10555-024-10166-x. Epub 2024 Jan 19. Cancer Metastasis Rev. 2024. PMID: 38238542 Free PMC article. Review.
-
The association of magnetic resonance imaging features with five molecular subtypes of breast cancer.Eur J Radiol Open. 2024 Jun 28;13:100585. doi: 10.1016/j.ejro.2024.100585. eCollection 2024 Dec. Eur J Radiol Open. 2024. PMID: 39041054 Free PMC article.
-
Survival analysis in breast cancer using proteomic data from four independent datasets.Sci Rep. 2021 Aug 18;11(1):16787. doi: 10.1038/s41598-021-96340-5. Sci Rep. 2021. PMID: 34408238 Free PMC article.
-
From Cell Lines to Patients: Dissecting the Proteomic Landscape of Exosomes in Breast Cancer.Diagnostics (Basel). 2025 Apr 17;15(8):1028. doi: 10.3390/diagnostics15081028. Diagnostics (Basel). 2025. PMID: 40310419 Free PMC article.
-
Pyrotinib promotes the antitumor effect of T-DM1 by increasing drug endocytosis in HER2-positive breast cancer.Sci Rep. 2025 May 28;15(1):18625. doi: 10.1038/s41598-025-03678-1. Sci Rep. 2025. PMID: 40437017 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous